Research Progress on the Mechanism of Androgen Receptor Signaling Pathway in Castration-Resistant Prostate Cancer DOI Creative Commons
Na Cui, Mingjie Li

annals of urologic oncology, Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 11, 2023

Prostate cancer (Pca) remains the most common malignancy worldwide in men, and second leading cause of mortality only to lung cancer. Besides surgery, androgen deprivation therapy (ADT) is a major treatment for Pca. However, ADT leads inevitable progression castration-resistant Pca (CRPC). The transition from hormone-dependent (ADPC) CRPC has been shown involve reactivation receptor (AR) signaling pathway. evidence become strong that develop adaptive mechanisms maintaining AR allow survival further evolution. This article mainly reviews research progress mechanism(s) provides scientific basis new ideas diagnosis this phenotype.

Language: Английский

RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy DOI
Zeyu Han,

Xianyanling Yi,

Jin Li

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(5), P. 188961 - 188961

Published: July 26, 2023

Language: Английский

Citations

7
Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review) DOI Creative Commons
Junjie Pan, Fei Tong, Ning Ren

et al.

Oncology Reports, Journal Year: 2024, Volume and Issue: 51(6)

Published: May 13, 2024

Prostate cancer (PCa) affects males of all racial and ethnic groups, leads to higher rates mortality in those belonging a lower socioeconomic status due the late detection disease. PCa middle‑aged between ages 45 60 years, is highest cause cancer‑associated Western countries. As most abundant common mRNA modification eukaryotes, N

Language: Английский

Citations

2
Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis DOI Creative Commons
Hongwei Zhang, Zixuan Wang,

Xiaolong Qiao

et al.

Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(1)

Published: June 17, 2024

Abstract Glioma is the most common malignant tumor of central nervous system, with EZH2 playing a crucial regulatory role. This study further explores abnormal expression and its mechanisms in regulating glioma progression. Additionally, it was found that IHMT-337 can potentially be therapeutic agent for glioma. The prognosis, expression, localization were determined using bioinformatics, IHC staining, Western blot (WB) analysis, immunofluorescence (IF) localization. effects on cell function assessed CCK-8 assays, Transwell wound healing assays. Public databases RT-qPCR utilized to identify downstream targets. these targets elucidated MS-PCR WB analysis. efficacy demonstrated through IC50 measurements, RT-qPCR. cells vitro evaluated EdU incorporation flow cytometry. potential as treatment blood–brain barrier (BBB) model an orthotopic model. Our research confirms significantly elevated gliomas, correlating patient prognosis. facilitates proliferation, migration, invasion alongside promoting SLC12A5 DNA methylation. By activates WNK1-OSR1-NKCC1 pathway, enhancing interaction ERM promote migration. inhibit WNK1 activation, thereby suppressing inhibits proliferation arrests cycle. has cross BBB successfully inhibited progression vivo. expands our understanding EZH2- axis laying new foundation clinical translation offering insights precision therapy.

Language: Английский

Citations

2
The emerging roles and mechanism of N6-methyladenosine (m6A) modifications in urologic tumours progression DOI Creative Commons
Wenhao Zhu, Renshan Zhao,

Xiaomin Guan

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: May 22, 2023

Prostate cancer (PCa), bladder (BC), and renal cell (RCC) are the most common urologic tumours in males. N6-methyladenosine (m 6 A), adenosine N6 methylation, is prevalent RNA modification mammals. Increasing evidence suggests that m A plays a crucial role development. In this review, we comprehensively analyzed influence of methylation on cancer, relationship between expression relevant regulatory factors their development occurrence, which provides new insights approaches for early clinical diagnosis targeted therapy malignancies.

Language: Английский

Citations

4
A potassium‐chloride co‐transporter with altered genome architecture functions as a suppressor in glioma DOI Creative Commons
Hongwei Liu,

Zhouyang Pan,

Xuelei Lin

et al.

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(9)

Published: April 29, 2024

Abstract Gliomas, the most lethal tumours in brain, have a poor prognosis despite accepting standard treatment. Limited benefits from current therapies can be attributed to genetic, epigenetic and microenvironmental cues that affect cell programming drive tumour heterogeneity. Through analysis of Hi‐C data, we identified potassium‐chloride co‐transporter SLC12A5 associated with disrupted topologically associating domain which was downregulated tissues. Multiple independent glioma cohorts were included analyse characterization found it significantly pathological features, prognostic value, genomic alterations, transcriptional landscape drug response. We constructed two overexpression lines verify function suppressed proliferation migration vitro. In addition, also positively GABA A receptor activity negatively pro‐tumour immune signatures immunotherapy Collectively, our study provides comprehensive supports as potential suppressor disease progression.

Language: Английский

Citations

1
The functions and mechanisms of RNA modification in prostate: Current status and future perspectives DOI Creative Commons
Zhijin Zhang, Ji Liu, Yang Wu

et al.

Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15

Published: May 10, 2024

The increasing incidence and mortality of prostate cancer worldwide significantly impact the life span male patients, emphasizing urgency understanding its pathogenic mechanism associated molecular changes that regulate tumor progression for effective prevention treatment. RNA modification, an important post-transcriptional regulatory process, profoundly influences cell growth metabolism, shaping fate. Over 170 modification methods are known, with prominent research focusing on N6-methyladenosine, N7-methylguanosine, N1-methyladenosine, 5-methylcytidine, pseudouridine, N4-acetylcytidine modifications. These alterations intricately coding non-coding post-transcriptionally, affecting stability protein expression levels. This article delves into latest advancements challenges various modifications in cells, microenvironment, core signaling molecule androgen receptors. It aims to provide new targets avenues diagnosis, treatment strategies, improvement prognosis cancer.

Language: Английский

Citations

1
Unraveling the Role of Long Non-Coding RNAs in Therapeutic Resistance in Acute Myeloid Leukemia: New Prospects & Challenges DOI Creative Commons
Siddhant Sharma

Non-coding RNA Research, Journal Year: 2024, Volume and Issue: 9(4), P. 1203 - 1221

Published: May 20, 2024

Acute Myeloid Leukemia (AML) is a fatal hematological disease characterized by the unchecked proliferation of immature myeloid blasts in different tissues developed various mutations hematopoiesis. Despite intense chemotherapeutic regimens, patients often experience poor outcomes, and many relapses leading to substandard remission rates. In recent years, long non-coding RNAs (lncRNAs) have increasingly become important prognostic therapeutic hotspots, due their contributions dysregulating functional epigenetic, transcriptional, post-translational mechanisms alterations cell expressions, resulting increased chemoresistance reduced apoptosis leukemic cells. Through this review, I highlight discuss latest advances understanding major through which lncRNAs confer therapy resistance AML. addition, also provide perspective on current strategies target lncRNA expressions. A better knowledge critical role that play controlling treatment outcomes AML will help improve existing medications devise new ones.

Language: Английский

Citations

1
ETV4‑mediated transcriptional activation of SLC12A5 exacerbates ferroptosis resistance and glucose metabolism reprogramming in breast cancer cells DOI
Huan Wang,

Yanyan Dai,

Fengxiang Wang

et al.

Molecular Medicine Reports, Journal Year: 2024, Volume and Issue: 30(6)

Published: Sept. 26, 2024

Solute carrier family 12 member 5 (SLC12A5) is an oncogene in numerous types of cancer, however its function breast cancer (BC) remains elusive. ETS translocation variant 4 (ETV4) promotes BC. Therefore, the present study aimed to elucidate role SLC12A5 ferroptosis and glucose metabolism BC cells as well understand underlying mechanism. Analysis data from UALCAN database demonstrated expression levels association with prognosis. Reverse transcription‑quantitative PCR western blotting were conducted evaluate ETV4 cells. The abilities proliferate, migrate invade assessed using Cell Counting Kit‑8, colony formation, wound healing Transwell assays. Thiobarbituric acid reactive substances assay a C11 BODIPY 581/591 probe used lipid peroxidation. Ferroptosis resistance was evaluated by measurement Fe

Language: Английский

Citations

1
Role of solute carrier transporters in ovarian cancer (Review) DOI Creative Commons
Barbara Quaresima, Stefania Scicchitano, Maria Concetta Faniello

et al.

International Journal of Molecular Medicine, Journal Year: 2024, Volume and Issue: 55(2)

Published: Nov. 27, 2024

Solute carrier (SLC) transporters are involved in various biological processes associated with metabolic reprogramming and cancer, supporting the increased requirement of nutrients energy. Over past decade, there have been significant advancements understanding expression function SLCs ovarian cancer (OC). This gynecological condition has a high mortality rate limited treatment options; thus, early diagnosis remains target clinically. OC exhibits complexity heterogeneity, resulting different clinical characteristics, resistance to chemotherapy drugs poor prognosis. Additionally, pattern between healthy tumor tissue, consequently, their inhibition or activation could modify signaling pathways growth process, such as cell proliferation, apoptosis drug accumulation. The present review aims consolidate current data provide comprehensive potential importance OC. it seeks offer guidance for further research on utilizing prognostic biomarkers therapeutic targets.

Language: Английский

Citations

1
Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities DOI Creative Commons
Mohammad B. Uddin, Zhishan Wang, Chengfeng Yang

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 11, 2024

Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although resistance is often reported along with temporary disease remission, there tumor recurrence an even more aggressive nature. Resistance currently available anticancer drugs results poor overall disease-free survival rates for patients. There are mechanisms through which cells develop agents. To date, efforts overcome only achieved limited success. Epitranscriptomics, especially related m

Language: Английский

Citations

1